Truist on Janux Therapeutics (JANX): 'The Post-Market Selloff Appears Overblown'
Tweet Send to a Friend
Truist Securities analyst Karina Rabayeva reiterated a Buy rating and $100.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
